Answers are grounded in this paper and cite their sources.
pharmacological studies and preclinical validation. Using pentacyclic triterpenes (PTs) as an example, this review summarizes research progress over the past 20 years on the biotransformation of four representative compounds, namely oleanolic acid (OA), glycyrrhizic acid (GL), ursolic acid (UA), and betulinic acid (BA), which belong to three key structural types of PTs. It focuses on clarifying the relationships between biocatalysts (wild-type and engineered microorganisms or enzymes) and substrates/products, as well as the correlations between compound structures and pharmacological activities, revealing the underlying patterns among them. The results indicated that the biotransformation of PTs by wild-type fungi/bacteria, enzymes, or engineered microorganisms exhibits marked strain specificity, diverse reaction pathways, and substantial product diversity. PT derivatives modified through biotransformation exhibit complex pharmacological effects in the tested cell lines, which depend specifically on their functional groups and substitution sites. Based on these findings, the establishment of a comprehensive information database covering the biotransformation of various NPs is proposed. Such a database can provide important support for the rational design of NP derivatives for further pharmacological evaluation based on NP biotransformation, facilitate the targeted design of biotransformation strategies, enable green and efficient access to highly active derivatives against specific diseases, reduce experimental error rates and research costs, and shorten the drug development cycle.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: